Inscripta stock

Inscripta Stock

HealthTech
Looking to sell Inscripta Stock or Options? Get a free valuation
Founded: 2015Funding to Date: $460M
Visit website

Inscripta has developed a gene-editing technology that provides scalable digital genome engineering with unparalleled simplicity. Their technology creates cost-effective libraries of thousands of bespoke protein, pathway, or genome variants, each with specific and trackable mutations. This empowers researchers to design, engineer, assess, and monitor results effectively and efficiently.

Investors Include:

GoldenArc, Venture Partners at CU Boulder, Vertical Venture Partners, Foresite Capital, iGlobe Partners, Spruceview Capital Partners, OMX Ventures, D1 Capital Partners, Fidelity Management & Research, Morgan Stanley, Oak HC/FT, Korys Investments, Venrock, ND Capital, Spruce Capital Partners, Phoenix International Investments, Durable Capital Partners, Counterpoint Global, JS Capital Management, Jonathan Feldstein, Paladin Capital Group, T. Rowe Price.

Own Inscripta stock or options?

Get an instant valuation

  • Completely free
  • 100% confidential & secure
  • Takes less than a minute
100% private & secure